Meeting
2023 ASCO Breakthrough
Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole.
Authors
Mai Abdel Gelil
Clinical Oncology Department, Assuit University, Assuit, Egypt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Local Disease
Clinical Trial Registration Number
PACTR202112813934276
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 8)
DOI
10.1200/GO.2023.9.Supplement_1.8
Abstract #
8
Poster Bd #
B2
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Cost-effectiveness of zoledronic acid (ZOL) in postmenopausal women with early breast cancer receiving adjuvant letrozole.
First Author: Mei Xue
Poster
2011 ASCO Annual Meeting
Bone effects of adjuvant tamoxifen (T), letrozole (L), or L plus zoledronic acid (Z) in early breast cancer (EBC): The phase III HOBOE study.
First Author: F. Perrone
Poster
2020 ASCO Virtual Scientific Program
Validation of MAF biomarker for response prediction to adjuvant bisphosphonates in 2 clinical trials: AZURE and NSABP-B34.
First Author: Alexander H. G. Paterson
Poster
2017 ASCO Annual Meeting
Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.
First Author: Francesco Perrone